If you don't think what I wrote is correct, please point out my errors. Please answer my question about where there is anything supporting your claim that "NNVC knew BASi FluCide1 tox testing would be inadmissible" and they did it "to relieve pressure" for appearances' sake.
I don't know why NNVC didn't complete tox testing on FluCide1. Reasonable guesses include: (1) problems with making enough in a standardized, reproducible manner; (2) problems devising the testing to see how the novel nanomedicine was absorbed, metabolized, distributed, and excreted; (3) a better FluCide came along, so they decided not to finish the early version; (4) a better business opportunity arose, namely topical HerpeCide, which would be quicker to market. What do your inside sources tell you was the reason? Please note "It's all a scam. These guys are good" is hard for many to believe without proof.
Please also share what your inside sources tell you what's new about FluCide2, how the HerpeCide opthalmic testing is going, or anything relevant here. We appreciate your inside information.
"the FDA will be putting extra scrutiny on all testing and results. My point was that based on this point that the company has made, and understanding how the FDA works, there is little likelihood that the Tox for Flucide 1 would in anyway be admissible for Flucide 2. If they're not the same ECAXT formula, something this NEW and UNIQUE will require it's own complete Tox."
Extra scrutiny by the FDA means ignoring a nearly identical FluCide or other nanoviricide toxicity results? Hard to buy that argument.
"Oh, wait, I know why none of this seems important...because NNVC is different, the normal rules and laws and commonly accepted procedures and requirements don't apply."
Huh? Who are you talking to, here? Did I say none of this is important, or that normal rules and laws and commonly accepted procedures and requirements don't apply?
To: Loanranger: I don't think companies usually provide transcripts to investors of FDA planning meetings. I'm going by what I recall hearing in 10-Ks "We will need to perform animal studies against a few additional strains of influenza viruses in order to substantiate that these drugs are indeed broad-spectrum drug candidates. Additional studies in cell cultures against different strains of influenza are also planned. All of these studies are necessary for filing an IND application." CEO letter from a while back, other PRs, and ...?
